



- (51) **International Patent Classification:**
A61K 38/17 (2006.01) *A61P 3/10* (2006.01)
C07K 14/775 (2006.01)
- (21) **International Application Number:**
PCT/US2012/021802
- (22) **International Filing Date:**
19 January 2012 (19.01.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/434,196 19 January 2011 (19.01.2011) US
- (71) **Applicant (for all designated States except US):** **UNIVERSITY OF CINCINNATI** [US/US]; 51 Goodman Drive, Suite 240, Cincinnati, OH 45221 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **TSO, Patrick** [US/US]; 51 Goodman Drive, Suite 240, Cincinnati, OH 45221 (US). **DAVIDSON, Sean** [US/US]; 51 Goodman Drive, Suite 240, Cincinnati, OH 45221 (US). **WOODS, Stephen** [US/US]; 51 Goodman Drive, Suite 240, Cincinnati, OH 45221 (US).

nati, OH 45221 (US). **WANG, Fei** [US/US]; 10811 Fall-sington Court, Cincinnati, OH 45242 (US).

- (74) **Agents:** **DAVIS, Steven, G.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

- (54) **Title:** APOLIPOPROTEIN AIV AS AN ANTIDIABETIC PEPTIDE




FIG. 1

(57) **Abstract:** Methods for treating type two diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type two diabetes mellitus are disclosed. The methods include administering an effective amount of apolipoprotein A-IV to the subject. The pharmaceutical composition includes apolipoprotein A-IV formulated for administration to a subject for the treatment of type two diabetes mellitus. Also disclosed are methods for substantially restoring glucose tolerance in a subject in need thereof to a normal level and methods for lowering blood glucose levels in a subject in need thereof.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*